ArticleCase reports in ophthalmological medicine2026
Rhino-Orbital-Cerebral Mucormycosis With Bilateral Endogenous
Article in Case reports in ophthalmological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rhino-Orbital-Cerebral Mucormycosis With Bilateral EndogenousCase reports in ophthalmological medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We report a diabetic patient with rhino-orbital-cerebral mucormycosis (ROCM) and bilateral endogenous Aspergillus endophthalmitis post-coronavirus disease 2019 (COVID-19) infection. Case Report: A 45-year-old man who had diabetes experienced vision loss and sought medical assistance. Prior to developing orbital symptoms, he had undergone intensive corticosteroid therapy for COVID-19. His uncorrected visual acuity was 20/20 in the right eye, but he had no light perception in his left eye. While hospitalized for ROCM, he developed endogenous endophthalmitis in his left eye, which was caused by Aspergillus fumigatus. Additionally, Aspergillus retinitis was diagnosed in his right eye due to the development of white retinal lesions and preretinal hemorrhage. To treat ROCM, he received systemic and retrobulbar injections of amphotericin B, which led to regression. Posaconazole was prescribed for the treatment of Aspergillus endophthalmitis. The retinitis lesions in his right eye responded well to oral posaconazole without any long-term complications. Conclusion: Patients with COVID-19-associated immunodeficiency may be more vulnerable to opportunistic pathogens, such as mucormycosis and Aspergillus, particularly if they have comorbidities like diabetes mellitus. It is also possible for one person to be coinfected with multiple opportunistic pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.